Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

119.08USD
26 May 2017
Change (% chg)

$0.74 (+0.63%)
Prev Close
$118.34
Open
$118.74
Day's High
$120.37
Day's Low
$118.67
Volume
230,059
Avg. Vol
240,490
52-wk High
$169.58
52-wk Low
$97.70

Latest Key Developments (Source: Significant Developments)

United Therapeutics Corp Q2 income per diluted share $4.39
Thursday, 28 Jul 2016 06:00am EDT 

United Therapeutics Corp Qtrly Non : United Therapeutics Corp qtrly net income, per diluted share $4.39 . Q2 earnings per share view $3.22, revenue view $395.0 million -- Thomson Reuters I/B/E/S . United Therapeutics Corporation reports second quarter 2016 financial results . Q2 revenue $400 million versus I/B/E/S view $395 million .Gaap earnings, per diluted share $4.55.  Full Article

United Therapeutics Corp says Roger Jeffs steps down as president and co-CEO
Thursday, 28 Apr 2016 06:31am EDT 

United Therapeutics Corp:Says Roger Jeffs steps down as president and co-chief executive officer.Says David Zaccardelli steps down as executive vice president and chief operating officer.United Therapeutics Corp says David Zaccardelli, steps down as executive vice president and chief operating officer.United Therapeutics Corp says Michael Benkowitz promoted to president and chief operating officer.United Therapeutics Corp says Martine Rothblatt, remains chairman of board and becomes sole chief executive officer.Says Michael Benkowitz promoted to president and chief operating officer.United therapeutics corp says Jeffs will become a senior advisor to company.  Full Article

United Therapeutics Corp announces additional $500 million share repurchase program
Thursday, 15 Oct 2015 06:00am EDT 

United Therapeutics Corp:Says authorized the repurchase of up to an additional $500 million of the company's common stock.Says program will become effective on January 1, 2016, and will remain open for up to one year.  Full Article

United Therapeutics Corp announces settlement of patent litigation with Sandoz Inc.
Wednesday, 30 Sep 2015 06:00am EDT 

United Therapeutics Corp:Says it has entered into a settlement agreement with Sandoz Inc relating to ongoing litigation concerning certain patents.Says under the settlement Agreement, United Therapeutics granted to Sandoz a non-exclusive license to manufacture and commercialize the generic version of Remodulin, although Sandoz may be permitted to enter the market earlier under certain circumstances.Says the settlement agreement does not grant Sandoz any rights other than those required to launch Sandoz's generic version of Remodulin.  Full Article

United Therapeutics Corporation agrees to sell priority review voucher to AbbVie
Wednesday, 19 Aug 2015 06:00am EDT 

United Therapeutics Corporation:Announces that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PPRV) to a subsidiary of AbbVie Inc.Says upon closing of the transaction, United Therapeutics will receive $350 million in cash in exchange for the PPRV.  Full Article

More From Around the Web

BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company

* United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company